Effect of Nitrofurantion Used as an Intracanal Medicament

Sponsor
Cairo University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05074628
Collaborator
(none)
38
2
24

Study Details

Study Description

Brief Summary

The aim of this study is to clinically evaluate the effect of Nitrofurantion on Intensity of Postoperative Pain and Bacterial Load Reduction, when compared to calcium hydroxide in teeth with necrotic pulp.

Condition or Disease Intervention/Treatment Phase
  • Drug: Nitrofurantoin capsules
Early Phase 1

Detailed Description

Nitrofurantoin has been used as a treatment for UTI since the 1950s. Evidence suggested that nitrofurantoin has excellent safety profile and lower resistance rates compared to recently introduced antimicrobials, recommending it as the first-line agent. Nitrofurantoin is convert to reactive intermediates by bacterial Nitroreductases. These intermediates were shown to attack bacterial ribosomal proteins non-specifically, causing complete inhibition of protein synthesis. In MIC, Nitrofurantoin specifically inhibit enzyme synthesis in bacteria (24). The lack of clinically significant bacterial resistance development to Nitrofurantoin is likely due to the multiple sites of attack and multiple mechanisms of action. Achievement of high local levels and low serum concentrations, and its effectiveness against both gram-negative and gram-positive bacteria provide many advantages that many of the newer agents do not have. After searching the database there is no clinical studies found yet on the effect of Nitrofurantoin antibiotic used as intracanal medicament in teeth with necrotic pulp. The aim of this study is to clinically evaluate the effect of Nitrofurantion on Intensity of Postoperative Pain and Bacterial Load Reduction, when compared to calcium hydroxide in teeth with necrotic pulp.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
38 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effect of Nitrofurantion Used as an Intracanal Medicament on the Intensity of Postoperative Pain and Bacterial Load Reduction Versus Calcium Hydroxide in Teeth With Necrotic Pulp: A Randomized Clinical Trial
Anticipated Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Nitrofurantion

is the drug of choice for the treatment of infections caused by multidrug resistant pathogens.

Drug: Nitrofurantoin capsules
methyl cellulose powder (MC) will be added to Nit solution to get a thick paste like consistency mixture.

Active Comparator: Calcium Hydroxide

Most commonly used intracanal medicaments . Antimicrobial activity of calcium hydroxide is related to the release of hydroxyl ions in an aqueous environment.

Drug: Nitrofurantoin capsules
methyl cellulose powder (MC) will be added to Nit solution to get a thick paste like consistency mixture.

Outcome Measures

Primary Outcome Measures

  1. Postoperative pain [2 Weeks]

    measured using numerical rating scale (NRS), 6, 12, 24, 48 hours:

Secondary Outcome Measures

  1. Bacterial load reduction [2 Weeks]

    determined by bacterial counting using agar culture technique after root canal preparation (CFU/ml).

  2. Incidence of inter-appointment flare up [2 Weeks]

    measured using visual analog scale of postoperative swelling (VAS).

  3. Incidence of analgesic intake [2 Weeks]

    numerical counting.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 1- Age between 18-50 years old. 2-Males or females. 3-Healthy patients whom are categorized as I or II according to The American Society of Anesthesiologists. (ASA I or II) 4-Patients' accepting to participate in the trial. 5-Patients who can understand pain scale and can sign the informed consent. 6- Mandibular Single rooted premolars, having single root canal:

  • Diagnosed clinically with pulp necrosis.

  • Absence of spontaneous pain

  • Slight widening in the periodontal membrane space or with periapical radiolucency not exceeding 2*2 mm radiographically.

  • Normal occlusal contact with opposing teeth.

Exclusion Criteria:
  • 1- Medically compromised patients having significant systemic disorders (ASA III or IV).

2-If analgesics or antibiotics have been administrated by the patient during the past 24 hours preoperatively as it might alter their pain perception.

3-Pregnant women: to avoid radiation exposure, anaesthesia, medication and hormonal Fluctuation that might increase pain prevalence.

4-Patients reporting bruxism, clenching, TMJ problems or traumatic occlusion: to avoid further pressure on inflamed tooth which induce subsequent irritation and inflammation.

5-Patients with two or more adjacent teeth requiring endodontic treatment. 6- Teeth that requires further procedural steps or multidisciplinary approach, which is out of this experiment's scope: i.Association with swelling or fistulous tract. ii. Acute periapical abscess. iii. Mobility Grade II or III. iv. Pocket depth more than 5mm. v. Previous root canal treatment. vi. Non-restorable. vii. Immature root. Vii. Radiographic evidence of external or internal root resorption, vertical root fracture, perforation, calcification.

7-Inability to perceive the given instructions.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Cairo University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Noha Mohamed Elsaber, Dr, Cairo University
ClinicalTrials.gov Identifier:
NCT05074628
Other Study ID Numbers:
  • ICM
First Posted:
Oct 12, 2021
Last Update Posted:
Oct 12, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Noha Mohamed Elsaber, Dr, Cairo University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 12, 2021